Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.53 |
---|---|
High | 20.62 |
Low | 20.34 |
Bid | 20.67 |
Offer | 20.70 |
Previous close | 20.45 |
Average volume | 1.61m |
---|---|
Shares outstanding | 661.77m |
Free float | 661.62m |
P/E (TTM) | 20.42 |
Market cap | 13.54bn USD |
EPS (TTM) | 1.00 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab Announces Financial Results for the First Nine Months of 2024
- Genmab to Present at Jefferies London Healthcare Conference
- Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
- Major Shareholder Announcement
- Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
- TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
More ▼